Free 7-day Trial
All Articles and Columns »

C.R. Bard Inc. Reports Operating Results (10-Q)

April 25, 2012 | About:
10qk

10qk

18 followers
C.R. Bard Inc. (BCR) filed Quarterly Report for the period ended 2012-03-31.

Bard C R Inc has a market cap of $8.32 billion; its shares were traded at around $97.13 with a P/E ratio of 15.3 and P/S ratio of 2.9. The dividend yield of Bard C R Inc stocks is 0.8%. Bard C R Inc had an annual average earning growth of 13.4% over the past 10 years. GuruFocus rated Bard C R Inc the business predictability rank of 5-star.
This is the annual revenues and earnings per share of BCR over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of BCR.


Highlight of Business Operations:

Bard’s United States net sales of $496.2 million for the quarter ended March 31, 2012 increased 2% compared to $487.1 million in the prior year quarter. Growth in United States net sales has moderated in recent quarters, a trend that may continue. International net sales of $233.8 million for the quarter ended March 31, 2012 increased 10% on a reported basis (11% on a constant currency basis) compared to $213.2 million in the prior year quarter.

Vascular Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products, electrophysiology products and vascular graft products. The increase in consolidated net sales of vascular products for the quarter ended March 31, 2012 compared to the prior year period was due primarily to growth in endovascular products. United States net sales of vascular products for the quarter ended March 31, 2012 increased 2% compared to the prior year quarter. International net sales of vascular products for the quarter ended March 31, 2012 increased 11% on a reported basis (13% on a constant currency basis) compared to the prior year quarter.

Urology Products - Bard markets a wide range of products for the urology market, including basic drainage products, continence products and urological specialty products. Bard also markets StatLock® catheter stabilization products, which are used to secure many types of catheters sold by Bard and other companies. The majority of basic drainage products, StatLock® catheter stabilization devices and certain urological specialty products are sold through distributors. Bard also markets Targeted Temperature Management™ products, acquired in November 2011, for therapeutic hypothermia. The increase in consolidated net sales of urology products for the quarter ended March 31, 2012 compared to the prior year period included 5 percentage points of growth on both a reported basis and constant currency basis from the addition of Targeted Temperature Management™ products, partially offset by a decrease in sales of continence products. United States net sales of urology products for the quarter ended March 31, 2012 increased 1% compared to the prior year quarter. International net sales of urology products for the quarter ended March 31, 2012 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year quarter.

Surgical Specialty Products - Surgical specialty products include soft tissue repair, performance irrigation and hemostasis product lines. United States net sales of surgical specialty products for the quarter ended March 31, 2012 decreased 2% compared to the prior year quarter. International net sales of surgical specialty products for the quarter ended March 31, 2012 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year quarter.

The company reported net income and diluted earnings per share available to common shareholders for the quarter ended March 31, 2012 of $138.7 million and $1.60, respectively. Net income and diluted earnings per share available to common shareholders for the prior year quarter were $131.9 million and $1.49, respectively. The current year quarter reflects acquisition-related items, primarily consisting of integration costs of $0.8 million, or $0.01 per diluted share. The prior year quarter reflects acquisition-related items, primarily consisting of an IPR&D charge of $1.8 million, or $0.02 per diluted share.

Read the The complete Report

About the author:

10qk
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide